ES2052370T3 - Peptidos o polipeptidos inmunologicamente activos del parvovirus b19. - Google Patents

Peptidos o polipeptidos inmunologicamente activos del parvovirus b19.

Info

Publication number
ES2052370T3
ES2052370T3 ES91903270T ES91903270T ES2052370T3 ES 2052370 T3 ES2052370 T3 ES 2052370T3 ES 91903270 T ES91903270 T ES 91903270T ES 91903270 T ES91903270 T ES 91903270T ES 2052370 T3 ES2052370 T3 ES 2052370T3
Authority
ES
Spain
Prior art keywords
gene
parvovirus
antigens
polypeptides
immunologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91903270T
Other languages
English (en)
Inventor
Erwin Soutschek
Manfred Motz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIKROGEN MOLEKULARBIOL ENTW
Original Assignee
MIKROGEN MOLEKULARBIOL ENTW
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIKROGEN MOLEKULARBIOL ENTW filed Critical MIKROGEN MOLEKULARBIOL ENTW
Application granted granted Critical
Publication of ES2052370T3 publication Critical patent/ES2052370T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14211—Erythrovirus, e.g. B19 virus
    • C12N2750/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE OBTIENEN PEPTIDOS O POLIPEPTIDOS ACTIVOS INMUNOLOGICAMENTE CON UN SECUENCIA DE AMINOACIDO PARCIAL DE LAS CAPSIDOPROTEINAS VP1 Y VP2 DEL PARVOVIRUS B19, QUE PERMITEN UNA REALIZACION DE PRUEBAS ECONOMICA, SENSITIVA Y ESPECIFICA PARA LA DETERMINACION DE LOS ANTICUERPOS CONTRA EL PARVOVIRUS HUMANO B19. SE IDENTIFICAN SECUENCIAS CORTAS DE PEPTIDOS QUE APLICADAS COMO ANTIGENO SIRVEN PARA LA IDENTIFICACION DE LOS SUEROS ANTI-B19-IGG POSITIVOS. ADEMAS, SE DESCRIBE LA PRODUCCION DE ESTOS PEPTIDOS CON MEDIDAS DE INGENIERIA GENETICA. OTROS ANTIGENOS PRODUCIDOS GENETICAMENTE, QUE SE PUEDEN OBTENER ESTABLES CON UN MAYOR RENDIMIENTO EN E. COLI Y QUE SE PUEDEN DEPURAR A PARTIR DE ESTOS A CONTINUACION, SIRVEN COMO ANTIGENOS ADICIONALES PARA LA PRUEBA DE LA IGG. FINALMENTE, UN CONJUNTO DE ANTIGENOS PERMITE LAS REALIZACIONES DE PRUEBAS PARA LA DETERMINACION DE LOS ANTICUERPOS IGM CONTRA EL VIRUS. ADICIONALMENTE, LOS COMPONENTES GENERADOS GENETICAMENTE DE LA PROTEINA SUPERFICIAL REPRESENTAN SUSTANCIAS QUESE PUEDEN UTILIZAR PARA UNA INMUNIZACION PROFILACTICA.
ES91903270T 1990-02-08 1991-02-08 Peptidos o polipeptidos inmunologicamente activos del parvovirus b19. Expired - Lifetime ES2052370T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4003826A DE4003826C2 (de) 1990-02-08 1990-02-08 Peptide der Kapsidproteine VP1 oder VP2 des Parvovirus B19

Publications (1)

Publication Number Publication Date
ES2052370T3 true ES2052370T3 (es) 1994-07-01

Family

ID=6399718

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91903270T Expired - Lifetime ES2052370T3 (es) 1990-02-08 1991-02-08 Peptidos o polipeptidos inmunologicamente activos del parvovirus b19.

Country Status (9)

Country Link
EP (1) EP0514413B1 (es)
JP (2) JP3061196B2 (es)
AT (1) ATE105303T1 (es)
AU (1) AU650864B2 (es)
CA (1) CA2075366C (es)
DE (2) DE4003826C2 (es)
DK (1) DK0514413T3 (es)
ES (1) ES2052370T3 (es)
WO (1) WO1991012269A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3149116B2 (ja) * 1992-10-28 2001-03-26 信越化学工業株式会社 ヒトパルボウイルスのエピトープ関連ペプチド
US5785974A (en) * 1993-01-23 1998-07-28 Immunologia Y Genetica Aplicada, S.A. Synthetic peptides and vaccines against parvovirus
WO1995011997A1 (en) * 1993-10-28 1995-05-04 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Adeno-associated virus - its diagnostic use with early abortion
WO1996027799A1 (en) * 1995-03-08 1996-09-12 Klaus Hedman Method for the diagnosis of infections
JPH0910000A (ja) 1995-06-26 1997-01-14 Nippon Sekijiyuujishiya ヒトパルボウイルスの検出方法及びそのための試薬
FR2771751B1 (fr) * 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris Erythrovirus et ses applications
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6743772B1 (en) 1998-11-24 2004-06-01 Kristina Broliden Use of parovirus capsid particles in the inhibition of cell proliferation and migration
US6818612B2 (en) 1998-11-24 2004-11-16 Kristina Broliden Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
KR100888377B1 (ko) 2001-06-28 2009-03-13 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 파르보바이러스 ｂ19의 진단 분석
US7094541B2 (en) 2001-08-31 2006-08-22 Gen-Probe Incorporated Assay for detection of human parvovirus B19 nucleic acid
WO2007096199A2 (en) * 2006-02-22 2007-08-30 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Differential diagnostics and therapy of virally induced heart muscle disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322417A1 (en) * 1986-09-08 1989-07-05 Applied Biotechnology, Inc. Empty viral capsid vaccines
DE3939470A1 (de) * 1989-11-29 1991-06-06 Biochrom Beteiligungs Gmbh & C Peptide und antikoerper gegen peptide, welche zur diagnose und zur verhuetung der b19-infektion verwendbar sind

Also Published As

Publication number Publication date
EP0514413A1 (de) 1992-11-25
DE4003826C2 (de) 1995-11-23
JP3130024B2 (ja) 2001-01-31
WO1991012269A1 (de) 1991-08-22
JP2000184889A (ja) 2000-07-04
CA2075366C (en) 2003-02-18
EP0514413B1 (de) 1994-05-04
JP3061196B2 (ja) 2000-07-10
DK0514413T3 (da) 1994-06-06
DE4003826A1 (de) 1991-08-14
AU650864B2 (en) 1994-07-07
ATE105303T1 (de) 1994-05-15
DE59101577D1 (de) 1994-06-09
AU7211591A (en) 1991-09-03
CA2075366A1 (en) 1991-08-09
JPH05504143A (ja) 1993-07-01

Similar Documents

Publication Publication Date Title
Dietzschold et al. Chemical and immunological analysis of the rabies soluble glycoprotein
DE69131149D1 (de) Synthetische Peptide, spezifisch zum Nachweis von gegen HCV gerichteten Antikörpern zur Diagnose der HCV-Infektion und zum Vorkommen davon als Impfstoffe
DE69327587T2 (de) Konjugate von schwach immunogenen antigenen und synthetischen peptidträgern und impfstoffe diese enthaltend
FI910720A (fi) Syntetiska peptider specifika foer detektering av hcv-antikroppar, diagnos av hcv-infektion och prevention av infektionen som vaccin.
ES2052370T3 (es) Peptidos o polipeptidos inmunologicamente activos del parvovirus b19.
DK0522030T3 (da) Hepatitis B-vaccine
YU152587A (sh) Monoklonska antitela i peptidi korisni u tretiranju i dijagnostifikovanju hiv-infekcija
Jemmerson et al. Mapping antigenic sites on proteins: Implications for the design of synthetic vaccines.
FI834590A (fi) Syntetisk picornavirus-antigen.
DK0469045T3 (da) Syntetiske Pseudomonas aeruginosa pilinpeptider og beslægtede vacciner diagnostica
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
GB2169606A (en) Liver fluke antigens
DE69017352T2 (de) An HIV relatierte Peptide.
Leroy Precipitating and complement-fixing antibodies to collagen with species and collagen subunit specificity
JPH03503416A (ja) ペプチド
ATE134648T1 (de) Künstliche polypeptide und antikörper in zusammenhang mit epstein-barr-virus-nuklear- antigen
Esandi Isolation and characterization of antibodies from sera of humans infected with Echinococcus granulosus
Emini et al. The immune response to poliovirus-specific synthetic peptides: effects of adjuvants and test animal species
Wilson et al. Autologous red cell agglutination test for antibodies to feline immunodeficiency virus
RU92004487A (ru) Днк, полипептид, вакцина, вектор, микроорганизм, клетка насекомого, реагент, способы лечения и профилактики, способ обнаружения антигенов

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 514413

Country of ref document: ES